Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015 BioSpecifics Technologies Corp. (NASDAQ: ... in class collagenase-based products marketed as XIAFLEX ® ... XIAPEX ®  in the EU, announced today that it ... at 8:30 a.m. ET on Friday, March 13, 2015 ... financial results and provide a corporate update. ...
(Date:3/6/2015)... 2015   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade hypothermic storage and ... shipping products for cells and tissues  ("BioLife" or ... full year 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:3/5/2015)... --  HX360 today announced that sixteen companies have ... Challenge competition. These companies, selected from a field ... one of four finalists to present their solutions live ... venture capitalists during the Innovation Challenge event. ... 2015 HIMSS Annual Conference & Exhibition, McCormick Place in ...
(Date:3/5/2015)... 05, 2015 Bi-Biomics today announced ... and stain additive. The improvement in histological quality ... features present in all daughter cells. , After ... packaging was analyzed at 1000-1600x using light microscopy. ... patterning in all daughter cells displayed predominant binary ...
Breaking Biology Technology:BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4
... Bedside Detection of Ischemic ... Infarction (Heart Attack), TEL AVIV, Israel, February 26 ... develops and markets systems for,non-invasive diagnosis and monitoring of ... using its proprietary,HyperQ technology in resting conditions., The ...
... today announced the,appointment of Douglas W. Axelrod, M.D., ... Development., Axelrod joins Ambrx after a productive ... Pharmaceuticals. Most recently, he served as,Vice President of ... he accelerated the discovery process, improved the,discovery to ...
... to join the Company, NATICK, Mass., Feb. 26 ... that Jay J. Schnitzer, M.D., Ph.D.,will be joining the ... will serve as Vice President and Associate Chief Medical,Officer, ... the Chief,Medical and Scientific Officer, Dr. Donald S. Baim, ...
Cached Biology Technology:BSP's New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study 2Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development 2Boston Scientific Announces Addition to Clinical Sciences Organization 2Boston Scientific Announces Addition to Clinical Sciences Organization 3Boston Scientific Announces Addition to Clinical Sciences Organization 4
(Date:2/5/2015)... , January 28, 2015 New ... Size And Segment Forecasts To 2020 has Been Added ... camera market is expected to reach USD 5.10 billion ... View Research, Inc. IR cameras help identify the site ... expected to witness surging demand in medical imaging applications. ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... DALLAS, April 3, 2012 /PRNewswire-iReach/ -- FirstMark today ... Regional Sales Manager for the Southeast region of the United ... primary role will be to drive growth and awareness for ... test that distinguishes the top 5 percent of suspected or ...
... EAST LANSING, Mich. For children with autism, being ... to increase the severity of their symptoms, according to ... autistic children who were born either preterm or post-term ... children born on time, revealed the study by Tammy ...
... Rodney Howell, MD, FACMG, is the recipient of the 2012 ... Dr. Howell is Professor of Pediatrics and Chairman Emeritus ... Miami. Dr. Howell, president of the American College of ... work in the field of pediatrics and genetic research and ...
Cached Biology News:FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager 2Autistic kids born preterm, post-term have more severe symptoms 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 2Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 3Renowned geneticist R. Rodney Howell receives ACMG Foundation Lifetime Achievement Award 4
... This kit is designed for the fast ... vector plasmids at any position (for the ... loxP-PGK-gb2-neo-loxP cassette is designed to allow neomycin ... cells. It combines a prokaryotic promoter (gb2) ...
... RoboSep is the first instrument to offer true ... EasySep technology to isolate cells by either positive ... up to 4 samples at one time. RoboSep ... The intuitive graphical user interface makes it simple ...
Plasmid expressing the LacZ reporter gene....
Plasmid expressing Zeocin resistance gene....
Biology Products: